BML-111
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


BML-111
Description :
BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2) . BML-111 has antiangiogenic, antitumor and anti-inflammatory properties[1][2].UNSPSC :
12352211Hazard Statement :
H302, H315, H319, H335Target :
Angiotensin-converting Enzyme (ACE)Type :
Reference compoundRelated Pathways :
Metabolic Enzyme/ProteaseApplications :
COVID-19-anti-virusField of Research :
Cancer; Inflammation/Immunology; Cardiovascular DiseaseAssay Protocol :
https://www.medchemexpress.com/bml-111.htmlPurity :
98.87Solubility :
DMSO : 200 mg/mL (ultrasonic)Smiles :
O=C(OC)CCC[C@H](O)[C@H](O)COMolecular Formula :
C8H16O5Molecular Weight :
192.21Precautions :
H302, H315, H319, H335References & Citations :
[1]Ying Chen, et al. Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis. Mol Cancer Ther. 2010 Aug;9 (8) :2164-74.|[2]Qiong-Feng Chen, et al. BML-111, a Lipoxin Receptor Agonist, Protects Against Acute Injury via Regulating the Renin Angiotensin-Aldosterone System. Prostaglandins Other Lipid Mediat. 2019 Feb;140:9-17.|[3]T H Lee, et al. Inhibition of Leukotriene B4-induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships. Biochem Biophys Res Commun. 1991 Nov 14;180 (3) :1416-21.Shipping Conditions :
Blue IceStorage Conditions :
-20°C, 3 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedCAS Number :
[78606-80-1]

